Patents by Inventor Barney Graham

Barney Graham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210275664
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 9, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Publication number: 20210198324
    Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.
    Type: Application
    Filed: March 15, 2021
    Publication date: July 1, 2021
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Peter Kwong, Ivelin Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Aliaksandr Druz, Ulrich Baxa, Joseph Van Galen, Cheng Cheng, John Mascola, Yaroslav Tsybovsky, Yongping Yang, Barney Graham, Syed Mohammad Moin, Jeffrey Boyington
  • Patent number: 10961283
    Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: March 30, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Kwong, Ivelin Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Aliaksandr Druz, Ulrich Baxa, Joseph Van Galen, Cheng Cheng, John Mascola, Yaroslav Tsybovsky, Yongping Yang, Barney Graham, Syed Mohammad Moin, Jeffrey Boyington
  • Patent number: 10960070
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: March 30, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Patent number: 10858400
    Abstract: Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: December 8, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter Kwong, Barney Graham, Jason McLellan, Man Chen, Baoshan Zhang, Tongqing Zhou, Michael Gordon Joyce, Yongping Yang
  • Publication number: 20200277338
    Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 3, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
  • Patent number: 10759846
    Abstract: Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: September 1, 2020
    Assignee: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Barney Graham, Wing-Pui Kong, Kayvon Modjarrad, Lingshu Wang, Wei Shi, Michael Gordon Joyce, Masaru Kanekiyo, John Mascola
  • Patent number: 10654898
    Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: May 19, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Serices
    Inventors: Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
  • Publication number: 20200102374
    Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.
    Type: Application
    Filed: September 10, 2019
    Publication date: April 2, 2020
    Inventors: Xavier SAELENS, Bert SCHEPENS, Iebe ROSSEY, Barney GRAHAM, Jason MCLELLAN, Morgan GILMAN
  • Publication number: 20200061185
    Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.
    Type: Application
    Filed: October 25, 2017
    Publication date: February 27, 2020
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Scripps Research Institute, Trustees of Dartmouth College
    Inventors: Barney Graham, Jason McLellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
  • Patent number: 10501528
    Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: December 10, 2019
    Assignees: V18 VZW, UNIVERSITEIT GENT, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Xavier Saelens, Bert Schepens, Iebe Rossey, Barney Graham, Jason McLellan, Morgan Gilman
  • Publication number: 20190330279
    Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 31, 2019
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Service
    Inventors: Peter Kwong, Ivelin Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Aliaksandr Druz, Ulrich Baxa, Joseph Van Galen, Rita Chen, Cheng Cheng, John Mascola, Yaroslav Tsybovsky, Yongping Yang, Paul Thomas, Barney Graham, Syed Mohammad Moin, Jeffrey Boyington, Kizzmekia Corbett
  • Publication number: 20190256579
    Abstract: Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 22, 2019
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Barney Graham, Wing-Pui Kong, Kayvon Modjarrad, Lingshu Wang, Wei Shi, Michael Gordon Joyce, Masaru Kanekiyo, John Mascola
  • Patent number: 10301377
    Abstract: Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: May 28, 2019
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Barney Graham, Wing-Pui Kong, Kayvon Modjarrad, Lingshu Wang, Wei Shi, Michael Gordon Joyce, Masaru Kanekiyo, John Mascola
  • Patent number: 10273288
    Abstract: Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: April 30, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine, The United States of America, as represented by the Secretary of the Army, Humabs Biomed SA
    Inventors: Nancy Sullivan, Sabue Mulangu, Davide Corti, Antonio Lanzavecchia, Barney Graham, Jean-Jacques Muyembe-Tamfun, John Trefry, Julie Ledgerwood, Daphne Stanley
  • Publication number: 20190112340
    Abstract: Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.
    Type: Application
    Filed: March 29, 2017
    Publication date: April 18, 2019
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human
    Inventors: Peter Kwong, Barney Graham, John Mascola, Li Ou, Aliaksandr Druz, Man Chen, Wing-Pui Kong, Ivelin Stefanov Georgiev, Emily Rundlet, Michael Gordon Joyce, Yaroslav Tsybovsky, Paul Thomas, Marie Pancera, Mallika Sastry, Cinque Soto, Joseph Van Galen, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Ulrich Baxa
  • Publication number: 20190071489
    Abstract: Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.
    Type: Application
    Filed: November 14, 2018
    Publication date: March 7, 2019
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine, The Government of the United States, as represented by the Secretary of the Army, Humabs BioMed SA
    Inventors: Nancy Sullivan, Sabue Malangu, Davide Corti, Antonio Lanzavecchia, Barney Graham, Jean-Jacques Muyembe-Tamfun, John Trefry, Julie Ledgerwood, Daphne Stanley
  • Patent number: 10160795
    Abstract: Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: December 25, 2018
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine, The United States of America as represented by the Secretary of the Army, Humabs BioMed SA
    Inventors: Nancy Sullivan, Sabue Mulangu, Davide Corti, Antonio Lanzavecchia, Barney Graham, Jean-Jacques Muyembe-Tamfun, John Trefry, Julie Ledgerwood, Daphne Stanley
  • Publication number: 20180312544
    Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.
    Type: Application
    Filed: January 20, 2016
    Publication date: November 1, 2018
    Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
  • Publication number: 20180291088
    Abstract: Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virususing the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virusinfection in a subject.
    Type: Application
    Filed: November 13, 2015
    Publication date: October 11, 2018
    Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, Institute for Research in Biomedicine, The Government of the United States as represented by the Secretary of the Army, Humabs BioMed SA
    Inventors: Nancy Sullivan, Sabue Mulangu, Davide Corti, Antonio Lanzavecchia, Barney Graham, Jean-Jacques Muyembe-Tamfun, John Trefry, Julie Ledgerwood, Daphne Stanley